Genetic testing for age-related macular degeneration: progress and perspectives

References

• National Eye Institute. Prevalence of age-related macular degeneration in the united states [NEI Statistics and Data]. Available from: www.nei.nih.gov/eyedata/pbd4.asp [Last accessed 15 May 2014]
   Google Scholar
• Fisher SA, Abecasis GR, Yashar B, et al. Meta-analysis of genome scans of age-related macular degeneration. Hum Mol Genet 2005;14:2257-64
   PubMed Web of Science ®Google Scholar
• National Eye Institute. The national ophthalmic disease genotyping and phenotyping network (eyeGENE). Available from: www.nei.nih.gov/resources/eyegene.asp [Last accessed 15 June 2014]
   Google Scholar
• Rosenfeld PJ, McKusick VA, Amberger JS, Dryja TP. Recent advances in the gene map of inherited eye disorders: primary hereditary diseases of the retina, choroid, and vitreous. J Med Genet 1994;31(12):903-15
   PubMed Web of Science ®Google Scholar
• Edwards AO, Ritter RIII, Abel KJ, et al. Complement factor H polymorphism and age-related macular degeneration. Science 2005;308:421-4
   PubMed Web of Science ®Google Scholar
• Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308:385-9
   PubMed Web of Science ®Google Scholar
• Weeks DE, Conley YP, Mah TS, et al. A full genome scan for age-related maculopathy. Hum Mol Genet 2000;9:1329-49
   PubMed Web of Science ®Google Scholar
• Klein ML, Schultz DW, Edwards A, et al. Age-related macular degeneration. Clinical features in a large family and linkage to chromosome 1q. Arch Ophthalmol 1998;116:1082-8
   PubMed Web of Science ®Google Scholar
• Dosso AA, Bovet J. Monozygotic twin brothers with age-related macular degeneration. Ophthalmologica 1992;205:24-8
   PubMed Web of Science ®Google Scholar
• Weeks DE, Conley YP, Tsai HJ, et al. Age-related maculopathy: a genomewide scan with continued evidence of susceptibility loci within the 1q31, 10q26, and 17q25 regions. Am J Hum Genet 2004;75:174-89
   PubMed Web of Science ®Google Scholar
• Kanda A, Chen W, Othman M, et al. A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. Proc Natl Acad Sci USA 2007;104:16227-32
   PubMed Web of Science ®Google Scholar
• Yang Z, Camp NJ, Sun H, et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science 2006;314(5801):992-3
   PubMed Web of Science ®Google Scholar
• Fritsche LG, Chen W, Schu M, et al. Seven new loci associated with age-related macular degeneration. Nat Genet 2013;45(4):433-9
   PubMed Web of Science ®Google Scholar
• Seddon JM, Yu Y, Miller EC, et al. Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat Genet 2013;45(11):1366-70
   PubMed Web of Science ®Google Scholar
• Zhan X, Larson DE, Wang C, et al. Identification of a rare coding variant in complement 3 associated with age-related macular degeneration. Nat Genet 2013;45(11):1375-9
   PubMed Web of Science ®Google Scholar
• van de Ven JP, Nilsson SC, Tan PL, et al. A functional variant in the CFI gene confers a high risk of age-related macular degeneration. Nat Genet 2013;45(7):813-17
   PubMed Web of Science ®Google Scholar
• Raychaudhuri S, Iartchouk O, Chin K, et al. A rare penetrant mutation in CFH confers high risk of age-related macular degeneration. Nat Genet 2011;43(12):1232-6
   PubMed Web of Science ®Google Scholar
• Helgason H, Sulem P, Duvvari MR, et al. A rare nonsynonymous sequence variant in C3 is associated with high risk of age-related macular degeneration. Nat Genet 2013;45(11):1371-4
   PubMed Web of Science ®Google Scholar
• Evans DG, Shenton A, Woodward E, et al. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 2008;8:155
   PubMed Web of Science ®Google Scholar
• Yu Y, Reynolds R, Rosner B, et al. Prospective assessment of genetic effects on progression to different stages of age-related macular degeneration using multistate Markov models. Invest Ophthalmol Vis Sci 2012;53(3):1548-56
   PubMed Web of Science ®Google Scholar
• Seddon JM, Cote J, Page WF, et al. The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. Arch Ophthalmol 2005;123(3):321-7
   PubMed Web of Science ®Google Scholar
• Stone EM, Aldave AJ, Drack AV, et al. Recommendations for genetic testing of inherited eye diseases: report of the american academy of ophthalmology task force on genetic testing. Ophthalmology 2012;119(11):2408-10
   PubMed Web of Science ®Google Scholar
• Stone EM. Genetic testing for age-related macular degeneration: not indicated now. JAMA Ophthalmol 2015;133(5):598-600
   Google Scholar
• Klein R, Klein BE, Tomany SC, et al. Ten-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 2002;109:1767-79
   PubMed Web of Science ®Google Scholar
• Ferris FL, Davis MD, Clemons TE, et al. A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol 2005;123(11):1570-4
   PubMed Web of Science ®Google Scholar
• Davis MD, Gangnon RE, Lee LY, et al. The age-related eye disease study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol 2005;123(11):1484-98
   PubMed Web of Science ®Google Scholar
• Seddon JM, Reynolds R, Maller J, et al. Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. Invest Ophthalmol Vis Sci 2009;50(5):2044-53
   PubMed Web of Science ®Google Scholar
• Klein ML, Francis PJ, Ferris FLIII, et al. Risk assessment model for development of advanced age-related macular degeneration. Arch Ophthalmol 2011;129(12):1543-50
   PubMed Web of Science ®Google Scholar
• Seddon JM, Reynolds R, Yu Y, et al. Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. Ophthalmology 2011;118(11):2203-11
   PubMed Web of Science ®Google Scholar
• Chen Y, Zeng J, Zhao C, et al. Assessing susceptibility to age-related macular degeneration with genetic markers and environmental factors. Arch Ophthalmol 2011;129(3):344-51
   PubMed Web of Science ®Google Scholar
• Hageman GS, Gehrs K, Lejnine S, et al. Clinical validation of a genetic model to estimate the risk of developing choroidal neovascular age-related macular degeneration. Hum Genomics 2011;5(5):420-40
   PubMedGoogle Scholar
• McCarthy LC, Newcombe PJ, Whittaker JC, et al. Predictive models of choroidal neovascularization and geographic atrophy incidence applied to clinical trial design. Am J Ophthalmol 2012;154:568-78
   PubMed Web of Science ®Google Scholar
• Perlee LT, Bansal AT, Gehrs KM, et al. Inclusion of Genotype with Fundus Phenotype Improves Accuracy of Predicting Choroidal Neovascularization and Geographic Atrophy. Ophthalmol 2013;120:1880-92
   PubMed Web of Science ®Google Scholar
• Seddon JM, Reynolds R, Yu Y, Rosner B. Validation of a prediction algorithm for progression to advanced macular degeneration subtypes. JAMA Ophthalmol 2013;131(4):448-55
   PubMed Web of Science ®Google Scholar
• Chiu CJ, Mitchell P, Klein R, et al. A risk score for the prediction of advanced age-related macular degeneration: development and validation in 2 prospective cohorts. Ophthalmology 2014;121(7):1421-7
   PubMedGoogle Scholar
• Scholl HP, Peto T, Dandekar S, et al. Inter- and intra-observer variability in grading lesions of age-related maculopathy and macular degeneration. Graefes Arch Clin Exp Ophthalmol 2003;241(1):39-47
   PubMed Web of Science ®Google Scholar
• Buitendijk GH, Rochtchina E, Myers C, et al. Prediction of age-related macular degeneration in the general population: the three continent AMD consortium. Ophthalmology 2013;120(12):2644-55
   PubMed Web of Science ®Google Scholar
• Combs R, McAllister M, Payne K, et al. Understanding the impact of genetic testing for inherited retinal dystrophy. Eur J Hum Genet 2013;21(11):1209-13
   PubMed Web of Science ®Google Scholar
• Abedi F, Wickremasinghe S, Richardson AJ, et al. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. Ophthalmology 2013;120(8):1641-8
   PubMed Web of Science ®Google Scholar
• Hagstrom SA, Ying GS, Pauer GJ, et al. Pharmacogenetics for genes associated with age-related macular degeneration in the comparison of AMD treatments trials (CATT). Ophthalmology 2013;120(3):593-9
   PubMed Web of Science ®Google Scholar
• Matsumiya W, Honda S, Yanagisawa S, et al. Evaluation of clinical and genetic indicators for the early response to intravitreal ranibizumab in exudative age-related macular degeneration. Pharmacogenomics 2014;15(6):833-43
   PubMed Web of Science ®Google Scholar
• Tsuchihashi T, Mori K, Horie-Inoue K, et al. Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration. Ophthalmology 2011;118(1):93-100
   PubMed Web of Science ®Google Scholar
• Hermann MM, van Asten F, Muether PS, et al. Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration. Ophthalmology 2014;121(4):905-10
   PubMed Web of Science ®Google Scholar
• Cruz-Gonzalez F, Cabrillo-Estévez L, López-Valverde G, et al. Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD. Graefes Arch Clin Exp Ophthalmol 2014;252(3):469-75
   PubMed Web of Science ®Google Scholar
• Finger RP, Wickremasinghe SS, Baird PN, Guymer RH. Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration. Surv Ophthalmol 2014;59(1):1-18
   PubMed Web of Science ®Google Scholar
• Chew EY, Klein ML, Clemons TE, et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology 2014;121(11):2173-80
   PubMed Web of Science ®Google Scholar
• Awh CC, Lane AM, Hawken S, et al. CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration. Ophthalmology 2013;120(11):2317-23
   PubMed Web of Science ®Google Scholar
• Botkin JR, Teutsch SM, Kaye CI, et al. Outcomes of interest in evidence-based evaluations of genetic tests. Gen Med 2010;12:228-35
   Google Scholar
• AREDS2-HOME Study Research Group. Chew EY, Clemons TE, et al. Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. Ophthalmology 2014;121(2):535-44
   PubMed Web of Science ®Google Scholar
• Rennie CA, Stinge A, King EA, et al. Can genetic risk information for age-related macular degeneration influence motivation to stop smoking? A pilot study. Eye (Lond) 2012;26(1):109-18
   PubMed Web of Science ®Google Scholar
• Linnenbringer E, Roberts JS, Hiraki S, et al. I know what you told me, but this is what I think: perceived risk of Alzheimer disease among individuals who accurately recall their genetics-based risk estimate. Genet Med 2010;12(4):219-27
   PubMed Web of Science ®Google Scholar
• Fanshawe TR, Prevost AT, Roberts JS, et al. Explaining behavior change after genetic testing: the problem of collinearity between test results and risk estimates. Genet Test 2008;12(3):381-6
   PubMedGoogle Scholar
• Genetic Information Nondiscrimination Act of 2008, National Human Genome Research Institute
   Google Scholar
• Neuner B, Komm A, Wellmann J, et al. Smoking history and the incidence of age-related macular degeneration–results from the muenster aging and retina study (MARS) cohort and systematic review and meta-analysis of observational longitudinal studies. Addict Behav 2009;34(11):938-47
   PubMed Web of Science ®Google Scholar